FDA delays verdict on Takeda colitis drug vedolizumab
This article was originally published in Scrip
Executive Summary
The US FDA has delayed its verdict on whether it will approve Takeda Pharmaceutical’s investigational biologic vedolizumab as a treatment for ulcerative colitis, extending the Prescription Drug User Fee Act (PDUFA) action date to 20 May 2014.